prodchem
Aug 31, 2026
Atmospheric water generation is attracting attention as an alternative source of freshwater, but its potential use in pharmaceutical manufacturing raises a much higher standard: producing water from air is not enough. Manufacturers must demonstrate consistent chemical, microbiological and particulate quality under tightly controlled conditions.
Water is one of the most important materials in pharmaceutical manufacturing.
It is used in drug formulation, cleaning, equipment preparation, laboratory testing and the production of active pharmaceutical ingredients.
Because water can come into direct or indirect contact with medicines, pharmaceutical manufacturers operate under stringent quality requirements.
This creates an important question for emerging atmospheric water generation technologies:
Can water extracted from ambient air be purified and controlled to meet pharmaceutical standards consistently?
The answer depends less on the initial source and more on the complete treatment, monitoring and validation system.
Atmospheric water generation, or AWG, captures water vapor from the surrounding air and converts it into liquid water.
Most systems use some combination of:
Air intake
Filtration
Cooling or desiccation
Condensation
Water collection
Purification
Storage
Disinfection
The technology is attractive because atmospheric air contains water vapor even in regions where conventional freshwater resources are limited.
However, the air being used as a water source is not necessarily clean.
That creates the first major pharmaceutical-quality challenge.
Ambient air can contain:
Dust
Particulate matter
Volatile organic compounds
Microorganisms
Industrial pollutants
Agricultural chemicals
Other airborne contaminants
When atmospheric moisture is condensed, some contaminants may enter the collected water.
The concentration and composition of contaminants will vary depending on:
Geographic location
Weather
Humidity
Industrial activity
Air pollution
Seasonal conditions
A system therefore cannot assume that atmospheric water has a consistent composition.
Pharmaceutical manufacturers do not simply require water that looks clean or tastes acceptable.
Water quality is evaluated according to defined chemical and microbiological specifications.
Depending on its intended use, pharmaceutical water may need to meet requirements related to:
Conductivity
Total organic carbon
Microbial quality
Endotoxins
Particulate contamination
Chemical impurities
Different grades of pharmaceutical water have different intended applications.
The critical distinction is therefore:
Freshwater source ≠ Pharmaceutical-grade water
A source becomes suitable for pharmaceutical use only after appropriate treatment, quality control and validation.
Pharmaceutical manufacturing commonly uses different water grades.
Purified Water (PW) is used in many manufacturing and cleaning applications.
Water for Injection (WFI) has more stringent requirements and is used in applications where control of microbial contamination and endotoxins is especially critical.
Atmospheric water generation therefore cannot be evaluated against a single universal standard.
The intended pharmaceutical application determines the required purification and control strategy.
Atmospheric water systems create several potential microbial-control challenges.
Air naturally contains microorganisms.
Condensation surfaces can also provide environments where microorganisms may accumulate if systems are not properly designed and maintained.
Once water has been collected, storage can introduce additional risks.
A pharmaceutical water system must therefore control:
Biofilm formation
Microbial growth
Dead legs
Stagnation
Storage conditions
Distribution-system contamination
The quality of water leaving the generator is only one part of the overall system.
Endotoxins are components associated with certain Gram-negative bacteria.
They can remain present even after bacteria themselves are no longer viable.
This creates a significant pharmaceutical concern.
A system that successfully kills microorganisms is not necessarily sufficient to control endotoxins.
For applications requiring highly controlled water, manufacturers need appropriate treatment and monitoring strategies.
Microbiological contamination can often be addressed through filtration, sanitization and controlled system design.
Chemical contamination may be more variable.
Atmospheric water could potentially contain compounds originating from the surrounding environment.
Depending on location, these could include traces of:
Organic compounds
Industrial pollutants
Volatile chemicals
Agricultural chemicals
Airborne particulates
The risk profile can therefore change as environmental conditions change.
This makes source-water characterization important.
For pharmaceutical applications, atmospheric water generation should be viewed as a water-source technology, not a complete pharmaceutical water solution.
The generated water may require additional treatment.
Possible purification technologies include:
Activated carbon
Microfiltration
Ultrafiltration
Reverse osmosis
Ion exchange
Ultraviolet treatment
Ozone treatment
Distillation
The exact combination depends on the quality of the incoming water and the intended application.
Reverse osmosis is widely used in water treatment because it can remove a broad range of dissolved contaminants.
However, reverse osmosis does not eliminate every risk by itself.
Membrane performance depends on:
Feed-water quality
Pressure
Temperature
Membrane condition
Fouling
System maintenance
Pharmaceutical systems therefore require monitoring rather than simply installing a purification unit and assuming the output will remain compliant.
Thermal distillation can provide highly purified water and has long been used in pharmaceutical applications.
However, it can require significant energy.
For atmospheric water systems, the overall sustainability equation therefore becomes more complicated.
A company may reduce dependence on conventional freshwater resources but increase energy consumption through:
Air dehumidification + Purification + Storage + Distribution
The environmental benefit must therefore be evaluated across the complete system.
Atmospheric water generation generally requires energy to remove moisture from air.
In humid environments, water extraction can be relatively favorable.
In dry environments, the energy required to capture each unit of water can increase.
This creates an important relationship:
Humidity ↑ → Potential water recovery ↑
Humidity ↓ → Energy requirement per unit of water may ↑
For pharmaceutical manufacturing, the system must therefore be evaluated not only for water quality but also for energy efficiency.
Unlike conventional municipal or purified-water supplies, atmospheric water availability depends directly on environmental conditions.
Humidity, temperature and air quality can vary throughout the year.
This creates challenges for pharmaceutical manufacturers that require highly consistent production inputs.
A validated system must demonstrate that changes in atmospheric conditions do not compromise the quality of the final pharmaceutical water.
Even if the water leaving the purification system is high quality, storage can introduce contamination.
Poorly designed tanks and distribution systems can allow:
Microbial growth
Biofilm formation
Chemical contamination
Stagnation
Pharmaceutical water systems therefore commonly use carefully controlled storage and distribution arrangements.
The objective is to maintain water quality from generation to point of use.
A pharmaceutical water system is not just a generator.
It is a network.
That network can include:
Generation → Purification → Storage → Distribution → Point of use
Each stage can introduce risk.
Validation therefore needs to consider the entire system.
This is particularly important when integrating an emerging technology such as atmospheric water generation into an existing pharmaceutical facility.
Pharmaceutical manufacturers cannot rely solely on occasional laboratory testing.
Critical water systems require appropriate monitoring programs.
Depending on the application, manufacturers may track:
Conductivity
Total organic carbon
Temperature
Microbial counts
Endotoxin levels
Pressure
Flow
Other process parameters
Continuous or frequent monitoring can help identify changes before they become major quality problems.
One of the most important lessons from pharmaceutical water systems is that quality must be designed into the process.
Testing the final product alone is not sufficient.
Instead, manufacturers need:
Controlled source
Validated treatment
Sanitary equipment
Defined operating conditions
Continuous monitoring
Documented maintenance
This principle applies particularly strongly to atmospheric water.
Despite the quality concerns, AWG could provide potential advantages in specific environments.
These may include:
Reduced dependence on centralized water infrastructure
Localized water production
Potential use in water-stressed regions
Greater supply resilience
Reduced transportation of water
For pharmaceutical companies operating in areas where water availability is a strategic concern, these advantages could be significant.
But sustainability benefits cannot come at the expense of product quality.
Atmospheric water generation can shift the resource equation.
Instead of relying primarily on conventional freshwater sources, the system relies on:
Air + Electricity + Purification Infrastructure
That means the environmental footprint depends heavily on the energy source.
If electricity comes from low-carbon sources, the overall environmental profile may improve.
If electricity is carbon-intensive, the benefit may be smaller.
A complete lifecycle assessment is therefore necessary.
Integrating atmospheric water systems with renewable energy could improve their sustainability profile.
Potential configurations could include:
Solar-powered generation
Renewable electricity procurement
On-site energy storage
Hybrid water-generation systems
However, pharmaceutical facilities still need reliable water supplies around the clock.
Backup power and redundancy may therefore be necessary.
One of the most important questions for pharmaceutical companies is not whether atmospheric water can be purified.
It is whether the complete system can be demonstrated to operate consistently under validated conditions.
Regulators are likely to focus on:
Water quality
System design
Monitoring
Sanitization
Maintenance
Validation
Change control
Documentation
The source of the water may be less important than the demonstrated quality and control of the final pharmaceutical water system.
Traditional pharmaceutical water systems often begin with relatively characterized source water.
Atmospheric water introduces greater environmental variability.
Air composition can change with:
Weather
Industrial emissions
Nearby agricultural activity
Seasonal pollution
Wildfire smoke
Urban development
The treatment system therefore needs sufficient robustness to accommodate changing conditions.
Reliability is particularly important for drug manufacturing.
A water-generation failure can interrupt production.
For this reason, atmospheric water systems may need to operate alongside conventional sources or backup systems.
A hybrid approach could provide:
Primary source + Atmospheric generation + Storage + Backup supply
Such redundancy could improve resilience while allowing the company to reduce dependence on a single water source.
Not every pharmaceutical water application requires the same quality level.
Atmospheric water could potentially be evaluated first for applications where treatment requirements are less demanding.
These might include certain:
Utility applications
Cleaning-related uses
Non-product-contact operations
Higher-purity applications would require substantially more rigorous validation.
This staged approach could allow manufacturers to evaluate the technology without immediately making it responsible for the most critical water requirements.
Modern pharmaceutical facilities increasingly use sensors and digital systems to monitor utilities.
Atmospheric water generation could benefit from monitoring:
Humidity
Air quality
Water production rate
Conductivity
Temperature
Total organic carbon
Microbial indicators
Filter performance
Data analytics could then identify changes in system performance.
Predictive maintenance could also help prevent failures.
AI and advanced analytics could potentially optimize atmospheric water systems by correlating:
Humidity + Temperature + Air Quality + Energy Consumption + Water Yield
This could help determine when atmospheric water generation is most efficient.
AI could also support predictive maintenance and detect abnormal water-quality patterns.
However, these technologies would supplement—not replace—validated pharmaceutical quality systems.
Water is often treated as a utility.
But for pharmaceutical manufacturing, it is also a supply-chain consideration.
Water shortages, droughts and infrastructure disruptions can affect production.
Localized water-generation technologies could therefore contribute to manufacturing resilience.
The strategic question becomes:
Can a pharmaceutical plant make part of its critical water supply more independent from external infrastructure without increasing quality risk?
For some facilities, atmospheric water generation could become part of that conversation.
Before adopting atmospheric water generation, manufacturers would need to evaluate several areas.
What contaminants are present in the surrounding air?
Can the purification system consistently remove relevant contaminants?
Can the system prevent microbial growth and biofilm formation?
Can the system consistently achieve the required endotoxin specifications where applicable?
How much electricity is required per unit of usable pharmaceutical water?
Can the system operate consistently under changing environmental conditions?
Can the entire generation, purification, storage and distribution system be validated?
Can the facility demonstrate ongoing control to regulators and auditors?
The debate surrounding atmospheric water generation highlights an important principle in pharmaceutical manufacturing:
The source of water is only the beginning of the quality equation.
Whether water comes from a municipal supply, groundwater, desalination or atmospheric moisture, it must be appropriately treated and controlled for its intended pharmaceutical application.
That makes water quality a systems-engineering challenge.
Atmospheric water generation offers an intriguing possibility for pharmaceutical manufacturers seeking alternative and potentially more resilient water sources.
But the technology faces a demanding test.
Pharmaceutical water must meet strict quality requirements, and those requirements apply throughout the entire system—from generation and purification to storage and final point of use.
Atmospheric water introduces additional variables because its starting conditions depend on humidity, temperature and air quality.
The most important challenge is therefore not simply whether water can be extracted from air.
It is whether that water can be transformed into a consistent, validated and reliably controlled pharmaceutical utility.
For manufacturers, the opportunity may lie in integrating atmospheric water generation with advanced purification, continuous monitoring, renewable energy and redundant supply systems.
If those elements can be combined successfully, atmospheric water could move beyond being an emerging sustainability technology and become part of a broader pharmaceutical strategy for water security, manufacturing resilience and resource efficiency.
Featured Product
Found this useful?
Continue Reading
A growing number of blue ammonia and low-carbon hydrogen projects face reconsideration in 2026 as costs, policy support and customer demand change. The trend offers important signals for chemical traders and procurement teams.
Woodside's reconsideration of its Texas blue ammonia unit carries direct relevance to fertilizer industry feedstock planning
This year's ACS Green Chemistry Challenge Awards specifically honored sustainable crop protection innovation
